| Entries |
| Document | Title | Date |
|---|
| 20080207631 | METHODS FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE CONDITIONS - Adatanserin is useful for treating neurodegenerative disorders, chronic pain, and other disorders associated with dysfunctional glutamate release. Methods of treating the same comprise administering a therapeutically effective amount of adatanserin or a pharmaceutical salt thereof, to a patient in need of said treatment. | 08-28-2008 |
| 20080261990 | Novel Pyrimidine Derivatives and their Use - The present invention relates to novel pyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular diseases, in particular dyslipidemias, arteriosclerosis, coronary heart disease, thrombosis and metabolic syndrome. | 10-23-2008 |
| 20080269237 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS - This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: | 10-30-2008 |
| 20080287455 | SULFANYL SUBSTITUTED PHENYL METHANONES - The present invention relates to compounds of formula I | 11-20-2008 |
| 20080306082 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases - The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases. | 12-11-2008 |
| 20080312248 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors - The invention relates to heteroaryl aryl ureas of the formula IA, | 12-18-2008 |
| 20090005393 | Pyridine and Pyrimidine Derivatives as Inhibitors of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 01-01-2009 |
| 20090030008 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS - Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): | 01-29-2009 |
| 20090036463 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 02-05-2009 |
| 20090076020 | Cyclopropyl Amide Derivatives 978 - Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith. | 03-19-2009 |
| 20090076021 | THERAPEUTIC COMBINATIONS AND METHODS FOR CARDIOVASCULAR IMPROVEMENT AND TREATING CARDIOVASCULAR DISEASE - A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand. | 03-19-2009 |
| 20090093493 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS - The invention relates to a new class of compounds, which are 1-phenylalcoxy-2-β-phenylethyl derivatives, as P-glycoprotein (P-GP) inhibitors. These compounds are useful in drug resistance events. They have been shown able to inhibit in a dose-dependent manner Glycoprotein-P (P-gp) activity in cell lines in which the expression of said glycoprotein is very high, like Caco-2 (human colon cancer) cells and MCF7/Adr (adriamycin-resistant human breast carcinoma) cells. The invention also relates to methods of production and the utilization of such compounds as medicaments useful in the treatment of states linked to the difficulty for some drugs to cross the blood-brain barrier (BBB) and generally within the context of the problems of drug resistance induced by chemotherapy agents. | 04-09-2009 |
| 20090093494 | 4-Pyrimidineamine Compounds And Uses As Anti-Proliferative Agents - The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers. | 04-09-2009 |
| 20090099194 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders - The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors or for the treatment of viral infections. The compounds provided interfere with the binding of SDF 1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis, or for reducing entry of HIV in to a cell while not reducing the capacity of the stem cells to proliferate. The compounds may be useful for long term treatment regimes. | 04-16-2009 |
| 20090105268 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors - A compound of formula M-L-M (I) wherein L is a linker and each M is independently a group of formula (II) is useful in therapy, e.g. of respiratory diseases. | 04-23-2009 |
| 20090143398 | PYRIMIDINYL-PIPERAZINES USEFUL AS D3/D2 RECEPTOR LIGANDS - The present invention relates to new dopamine D | 06-04-2009 |
| 20090149466 | INHIBITORS OF STEAROYL-COA DESATURASE - Provided herein are compounds of the formula (I): | 06-11-2009 |
| 20090170864 | Diacylglycerol Acyltransferase Inhibitors - Provided herein are compounds of the formula (I): | 07-02-2009 |
| 20090247537 | METHODS FOR PREVENTING OR TREATING BRUXISM USING DOPAMINERGIC AGENTS - Methods for preventing or treating bruxism, including alleviating or eliminating one or more symptoms, diseases or conditions associated with or resulting from bruxism, using dopaminergic agents such as monoamine oxidase inhibitors that increase dopaminergic activity and dopamine agonists, are disclosed. | 10-01-2009 |
| 20090286801 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS - The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent. | 11-19-2009 |
| 20090312341 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT - Disclosed are novel compounds of the formula | 12-17-2009 |
| 20100010003 | Pyrimidine Derivatives And Their Use As Pesticides - The invention relates to new pyrimidine compounds of formula (1) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (1) are useful in the control of parasites, in particular ectoparasites, in and on warmblooded animals. | 01-14-2010 |
| 20100010004 | INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 01-14-2010 |
| 20100113467 | Organic Compounds - The invention relates to naphthalene carboxylic acid and isoquinoline carboxylic acid amides, and related compounds of formula I | 05-06-2010 |
| 20100331340 | USE OF ARYL PIPERAZINE DERIVATIVES IN MANUFACTURING MEDICANTS FOR TREATING PAIN - The use of aryl piperazines of formula (I) in manufacturing a medicament for treating acute pain, neuropathic pain or receptive nociceptive pain in mammals including human beings is disclosed. | 12-30-2010 |
| 20110039858 | Novel Compounds - The invention relates to at least one compound of general formula I | 02-17-2011 |
| 20110071158 | NEW COMPOUNDS - The present invention encompasses compounds of general formula (1) | 03-24-2011 |
| 20110183991 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME - The present invention relates to compounds having pharmacological activity towards the 5-HT | 07-28-2011 |
| 20110207739 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof - A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer. | 08-25-2011 |
| 20110230494 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 09-22-2011 |
| 20110237598 | NEW COMPOUNDS - The present invention encompasses compounds of general formulae (1 | 09-29-2011 |
| 20110319420 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR - The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR. | 12-29-2011 |
| 20120108603 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 05-03-2012 |
| 20120129867 | INHIBITORS OF PROTEIN KINASES - The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. | 05-24-2012 |
| 20120172369 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (DGAT) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: | 07-05-2012 |
| 20120245182 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1--1-METHYL-UREA AND SALTS THEREOF - The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt, and the hydrochloride salt, including its dihydrate. The present technology further provides methods for preparing the various forms, compositions containing them, and methods of treatment employing them. | 09-27-2012 |
| 20130018056 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 01-17-2013 |
| 20130123269 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF - The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): | 05-16-2013 |
| 20130197009 | ANTAGONIST FOR MUTANT ANDROGEN RECEPTOR - [Problem] An object of the present invention is to provide a novel anticancer drug which is useful for treating prostate cancer accompanying androgen receptor mutation | 08-01-2013 |
| 20130245034 | Inhibitors Of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 09-19-2013 |
| 20130267530 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same. | 10-10-2013 |
| 20130267531 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same. | 10-10-2013 |
| 20130267532 | CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE - The invention concerns compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein n, R | 10-10-2013 |
| 20130324546 | SELECTIVE FAK INHIBITORS - A compound of the formula (I): | 12-05-2013 |
| 20130345231 | ANTICANCER THERAPEUTIC AGENTS - The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy. | 12-26-2013 |
| 20140031361 | INHIBITORS OF PROTEIN KINASES - The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. | 01-30-2014 |
| 20140088113 | METHODS AND KITS THAT IDENTIFY TUMORS RESPONSIVE TO SRC INHIBITORS - Disclosed herein are methods of predicting whether or not a subject will benefit from treatment with a Src inhibitor on the basis of the expression of one or more of Von Hippel Lindau (VHL), Src, PTP1B, pFAK, HIF-1α, and/or CA-IX in a tumor sample from the subject. | 03-27-2014 |
| 20140171439 | Inhibitors Of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 06-19-2014 |
| 20140194437 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR - The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. | 07-10-2014 |
| 20140275104 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR - The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. | 09-18-2014 |
| 20140275105 | CRYSTAL OF ANDROGEN RECEPTOR ANTAGONISTIC COMPOUND - [Problem] A crystal of (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide with excellent activity as an androgen receptor (AR) antagonistic compound, the salts thereof, or the solvate thereof, which is suitable for industrialization as a bulk drug of pharmaceutical products; a pharmaceutical composition comprising the crystal as an active ingredient; and the pharmaceutical composition which is the AR antagonistic drug are provided. | 09-18-2014 |
| 20140303176 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR - The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. | 10-09-2014 |
| 20140378468 | N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea - An N-oxide of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]pyrimidin-4-yl}-1-methyl-urea, pharmaceutically acceptable salts thereof, compositions including the compound and its pharmaceutically acceptable salts, and methods of preparing the compound and the compositions (such as, for example, by oxidizing 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea with an oxidizing agent) are described. Further described herein are methods of using the compound and compositions of the present technology, alone and in combination with other suitable agents, to treat various diseases, including but not limited to, those that can be prevented, inhibited or ameliorated by inhibition of kinase activity selected from FGFR1, FGFR2, FGFR3 or FGFR4. | 12-25-2014 |
| 20150011560 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 - The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant or FGFR3. | 01-08-2015 |
| 20150011561 | Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor - The present invention provides a compound of formula (I) | 01-08-2015 |
| 20150045370 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER - The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders. | 02-12-2015 |
| 20150105399 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS - Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds are central analgesics regulating 5-hydroxytrptamine, and also are novel antidepressants regulating 5-hydroxytrptamine. This class of compounds also has less toxic and side effects and a higher safety range. The 3-cyanoanilinoalkylarylpiperazine derivative is a compound shown as formula (III) or free base or salt thereof: | 04-16-2015 |
| 20150105400 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-β, IL-1β, IL-6 and MCP-1 and the like. | 04-16-2015 |
| 20150141434 | PYRIDINE AND PIPERIDINE DERIVATIVES AND USE THEREOF - The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I: | 05-21-2015 |
| 20150323548 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS - The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and/or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses. | 11-12-2015 |
| 20150344441 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same. | 12-03-2015 |
| 20150374693 | Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor - The present invention provides a compound of formula (I) | 12-31-2015 |
| 20160009661 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | 01-14-2016 |
| 20160022677 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same. | 01-28-2016 |
| 20160024063 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT - The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc. | 01-28-2016 |
| 20160095842 | COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER - A pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof and a fibroblast growth factor receptor (FGFR) kinase inhibitor, particularly for simultaneous, separate or sequential use for the treatment of a cancer; use of such pharmaceutical combination for the preparation of a medicament for the treatment of a cancer; use of such pharmaceutical combination for the treatment a cancer; a method for treating a cancer comprising administering to a subject having said cancer a jointly therapeutically effective amount of such combination; and related pharmaceutical compositions or kits thereof. | 04-07-2016 |
| 20160102062 | N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea - An N-oxide of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, pharmaceutically acceptable salts thereof, compositions including the compound and its pharmaceutically acceptable salts, and methods of preparing the compound and the compositions (such as, for example, by oxidizing 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea with an oxidizing agent) are described. Further described herein are methods of using the compound and compositions of the present technology, alone and in combination with other suitable agents, to treat various diseases, including but not limited to, those that can be prevented, inhibited or ameliorated by inhibition of kinase activity selected from FGFR1, FGFR2, FGFR3 or FGFR4. | 04-14-2016 |
| 20160129000 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 05-12-2016 |
| 20160375023 | NOVEL FGFR3 FUSION - The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided. | 12-29-2016 |
